• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用异速生长原理,根据动物数据预测AT1受体拮抗剂厄贝沙坦的人体药代动力学参数。

Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

作者信息

Kumar Venkata V Pavan, Srinivas Nuggehally R

机构信息

Integrated Drug Development, Suramus Biopharm, J.P. Nagar I Phase, Bangalore 560078, India.

出版信息

Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):247-52. doi: 10.1007/BF03190880.

DOI:10.1007/BF03190880
PMID:19230599
Abstract

Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.

摘要

异速生长原理已被应用于估算和预测重要的AT1受体拮抗剂厄贝沙坦的人体药代动力学参数。在异速生长分析中使用了从大鼠、猕猴(猴子)和狗收集的临床前数据。使用这些物种是合理的,因为基于这些物种的临床前模型已用于评估厄贝沙坦的药效学活性。通过简单的异速生长法(CL/F、V/F和Kel)或使用校正因子(CL/F)对清除率(CL/F)、分布容积(V/F)和消除速率常数(Kel)的人体参数值进行了估算。厄贝沙坦的CL/F和消除半衰期(T1/2)(使用Kel)预测值似乎与各自报道的人体值非常接近(CL/F:预测值 = 18 L/h,观察值 = 22.2 L/h;T1/2:预测值 = 9 h;观察值 = 10 - 20 h);而使用简单异速生长法时,V/F值略微高估了1.75倍(预测值 = 456 L;观察值 = 260 L)。本研究为属于这一重要治疗类别的化合物进行前瞻性异速生长缩放提供了机会。

相似文献

1
Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.应用异速生长原理,根据动物数据预测AT1受体拮抗剂厄贝沙坦的人体药代动力学参数。
Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):247-52. doi: 10.1007/BF03190880.
2
Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.应用比例模型法改善人体口服给药后的血药峰浓度、分布容积和半衰期的预测。
Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000.
3
Allometric modeling of ciclesonide, a nonhalogenated glucocorticoid, and its active metabolite, desisobutyrylciclesonide, using animal-derived pharmacokinetic parameters.使用动物来源的药代动力学参数对非卤化糖皮质激素环索奈德及其活性代谢物去异丁酰环索奈德进行人体外的比例模型研究。
Am J Ther. 2013 May-Jun;20(3):261-6. doi: 10.1097/MJT.0b013e31819df738.
4
Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.厄贝沙坦(一种血管紧张素II AT1受体拮抗剂)在小鼠、大鼠、兔子和猕猴体内的处置情况。
Drug Metab Dispos. 2000 Jan;28(1):79-88.
5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.应用动物种属放大法进行人源 UDP-葡糖醛酸基转移酶底物的药代动力学预测。
Drug Metab Dispos. 2011 May;39(5):820-9. doi: 10.1124/dmd.110.037457. Epub 2011 Jan 31.
6
Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.格列吡嗪单剂量及多剂量治疗对正常大鼠和高血压大鼠中厄贝沙坦药代动力学和药效学的影响
High Blood Press Cardiovasc Prev. 2017 Jun;24(2):179-185. doi: 10.1007/s40292-017-0195-2. Epub 2017 Apr 6.
7
Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones.通过异速生长标度法利用动物数据预测利奈唑胺的临床药代动力学参数:对新型恶唑烷酮类药物开发的适用性
Xenobiotica. 2004 Jun;34(6):571-9. doi: 10.1080/00498250410001685719.
8
Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.新型经胆汁排泄的PPAR双重激动剂瑞格列扎的临床前药代动力学及种间缩放
Eur J Drug Metab Pharmacokinet. 2007 Jan-Mar;32(1):29-37. doi: 10.1007/BF03190987.
9
Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions.厄贝沙坦在肾性高血压犬非稳态和稳态条件下的药代动力学和药效学
Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1-2):121-6. doi: 10.1007/BF03226417.
10
[Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].长效血管紧张素受体阻滞剂(ARB)厄贝沙坦的药理特性及临床疗效
Nihon Yakurigaku Zasshi. 2009 May;133(5):275-80. doi: 10.1254/fpj.133.275.

引用本文的文献

1
Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach.使用异速生长法对非甾体抗炎药酮咯酸的人体药代动力学参数进行静脉预测。
Eur J Drug Metab Pharmacokinet. 2011 Jun;36(2):87-93. doi: 10.1007/s13318-011-0029-x. Epub 2011 Mar 5.

本文引用的文献

1
Allometric prediction of the human pharmacokinetic parameters for naveglitazar.那格列净的人体药代动力学参数的异速生长预测。
Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):187-90. doi: 10.1007/BF03191117.
2
Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.喜树碱类似物的种间剂量换算:利用动物数据预测人体静脉注射拓扑替康的剂量
Xenobiotica. 2008 Nov;38(11):1377-85. doi: 10.1080/00498250802488577.
3
Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.
新型经胆汁排泄的PPAR双重激动剂瑞格列扎的临床前药代动力学及种间缩放
Eur J Drug Metab Pharmacokinet. 2007 Jan-Mar;32(1):29-37. doi: 10.1007/BF03190987.
4
Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs.厄贝沙坦与氢氯噻嗪在肾性高血压犬体内的药代动力学和药效学相互作用。
J Cardiovasc Pharmacol. 2005 Dec;46(6):863-9. doi: 10.1097/01.fjc.0000191289.35182.7e.
5
Interspecies scaling of biliary excreted drugs: a comparison of several methods.胆汁排泄药物的种间剂量换算:几种方法的比较
J Pharm Sci. 2005 Apr;94(4):883-92. doi: 10.1002/jps.20313.
6
Interspecies scaling of biliary excreted drugs.经胆汁排泄药物的种间剂量换算
J Pharm Sci. 2002 Aug;91(8):1908-14. doi: 10.1002/jps.10174.
7
Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.厄贝沙坦(一种血管紧张素II AT1受体拮抗剂)在小鼠、大鼠、兔子和猕猴体内的处置情况。
Drug Metab Dispos. 2000 Jan;28(1):79-88.
8
Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.血管紧张素拮抗剂厄贝沙坦在健康志愿者中的口服生物利用度及处置特征。
J Clin Pharmacol. 1998 Aug;38(8):702-7. doi: 10.1002/j.1552-4604.1998.tb04809.x.
9
Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.厄贝沙坦在肝硬化患者中的药代动力学和药效学
J Clin Pharmacol. 1998 Apr;38(4):347-56. doi: 10.1002/j.1552-4604.1998.tb04434.x.
10
Biotransformation of irbesartan in man.厄贝沙坦在人体内的生物转化。
Drug Metab Dispos. 1998 May;26(5):408-17.